Paper36923538
FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.
Chen X and 11 others. Theranostics, 2023. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC. Papers, record 36923538. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923538
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptor, Fibroblast Growth Factor, Type 4 | Major topic |
| Colorectal Neoplasms | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Cell Proliferation | |
| Neoplasm Metastasis | |
| DNA-Binding Proteins | |
| Transcription Factors | |
| Fibroblast Growth Factors |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33456563 | CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. | Theranostics | 2021 | https://conductscience.org/library/papers/33456563 | PubMed |
| 2 | 21552992 | Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. | Invest New Drugs | 2012 | https://conductscience.org/library/papers/21552992 | PubMed |
| 3 | 27932483 | Roles and regulations of the ETS transcription factor ELF4/MEF. | J Mol Cell Biol | 2017 | https://conductscience.org/library/papers/27932483 | PubMed |
| 4 | 26921333 | Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer. | Cancer Res | 2016 | https://conductscience.org/library/papers/26921333 | PubMed |
| 5 | 33334065 | Tribbles Pseudokinase 3 Contributes to Cancer Stemness of Endometrial Cancer Cells by Regulating β-Catenin Expression. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33334065 | PubMed |
| 6 | 24874735 | Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer. | Cell Death Dis | 2014 | https://conductscience.org/library/papers/24874735 | PubMed |
| 7 | 18593907 | Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. | Cancer Res | 2008 | https://conductscience.org/library/papers/18593907 | PubMed |
| 8 | 31575540 | Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31575540 | PubMed |
| 9 | 19809159 | Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. | J Clin Invest | 2009 | https://conductscience.org/library/papers/19809159 | PubMed |
| 10 | 33713299 | Tirbanibulin: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/33713299 | PubMed |
| 11 | 36209117 | Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/36209117 | PubMed |
| 12 | 23943801 | FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. | Cancer Res | 2013 | https://conductscience.org/library/papers/23943801 | PubMed |
| 13 | 25854696 | FGF19 promotes progression of prostate cancer. | Prostate | 2015 | https://conductscience.org/library/papers/25854696 | PubMed |
| 14 | 21852023 | Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. | Eur J Med Chem | 2011 | https://conductscience.org/library/papers/21852023 | PubMed |
| 15 | 36352028 | PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. | Br J Cancer | 2023 | https://conductscience.org/library/papers/36352028 | PubMed |
| 16 | 36598638 | Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis. | Cell Oncol (Dordr) | 2023 | https://conductscience.org/library/papers/36598638 | PubMed |
| 17 | 19247306 | The FGF family: biology, pathophysiology and therapy. | Nat Rev Drug Discov | 2009 | https://conductscience.org/library/papers/19247306 | PubMed |
| 18 | 33591350 | Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. | JAMA | 2021 | https://conductscience.org/library/papers/33591350 | PubMed |
| 19 | 21747170 | Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. | J Clin Invest | 2011 | https://conductscience.org/library/papers/21747170 | PubMed |
| 20 | 30070748 | Role of fibroblast growth factor receptor 4 in cancer. | Cancer Sci | 2018 | https://conductscience.org/library/papers/30070748 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42737619 | Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737619 | PubMed |
| 42724722 | Prognostic and clinicopathologic significance of FGFR mRNA and protein overexpression in colorectal cancer: a systematic review and meta-analysis. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724722 | PubMed |
| 42633326 | Advances in FGF/FGFR Signaling: Implications for Disease and Therapy. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42633326 | PubMed |
| 42463639 | Dual-faced metabolic reprogramming powers proliferation: FGF21 drives lung squamous carcinoma progression via CaMKII-DRP1-mediated mitochondrial fission. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42463639 | PubMed |
| 42180975 | Construction of a prognostic risk model based on colorectal cancer-specific ferroptosis genes and preliminary validation of FGFR4. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180975 | PubMed |
| 42149884 | In-silico prediction of multi‑target mechanisms of Pinellia ternata phytochemicals in lung cancer: Evidence from a graph‑attention‑guided virtual screening and multi‑scale simulations. | PLoS One | 2026 | https://conductscience.org/library/papers/42149884 | PubMed |
| 41918035 | Integrative genomic profiling of iron homeostasis predicts clinical outcomes and identifies HAMP/hepcidin as a therapeutic target in colorectal cancer. | Cell Biosci | 2026 | https://conductscience.org/library/papers/41918035 | PubMed |
| 41821016 | Targeting the FGF19/FGFR4 positive feedback loop to disrupt ERK-mediated tumor progression in head and neck cancer. | J Transl Med | 2026 | https://conductscience.org/library/papers/41821016 | PubMed |
| 41789601 | lncRNA AL445238.2‑USP4 axis regulates cell survival and stemness in colon cancer. | Int J Oncol | 2026 | https://conductscience.org/library/papers/41789601 | PubMed |
| 41681889 | Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681889 | PubMed |
| 41666187 | Exploring the crosstalk between the FGF/FGFR pathway and tumor microenvironment in clear cell renal cell carcinoma. | PLoS One | 2026 | https://conductscience.org/library/papers/41666187 | PubMed |
| 41631414 | Colorectal cancer-derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver. | Mol Oncol | 2026 | https://conductscience.org/library/papers/41631414 | PubMed |
| 41551579 | Mechanistic study of glutamine metabolic reprogramming driving non-small cell lung cancer progression via the FGF17-FGFR4 axis mediating epithelial-mesenchymal transition. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/41551579 | PubMed |
| 41407838 | Development and validation of a CAF-related signature for prognosis and therapy response in colorectal cancer: new insights on HSPB1. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/41407838 | PubMed |
| 41328353 | FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities. | Theranostics | 2026 | https://conductscience.org/library/papers/41328353 | PubMed |
| 41287970 | ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer. | J Cell Physiol | 2025 | https://conductscience.org/library/papers/41287970 | PubMed |
| 41210688 | Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway. | J Cancer | 2025 | https://conductscience.org/library/papers/41210688 | PubMed |
| 41179295 | RAD23B Promotes Colorectal Cancer Metastasis via the Talin1/Integrin/PI3K/AKT/MMP9 Axis. | Oncol Res | 2025 | https://conductscience.org/library/papers/41179295 | PubMed |
| 41074024 | Integrating the secretome and interactome to identify novel biomarkers and therapeutic targets in colorectal cancer. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/41074024 | PubMed |
| 41002393 | The Colonic Crypt: Cellular Dynamics and Signaling Pathways in Homeostasis and Cancer. | Cells | 2025 | https://conductscience.org/library/papers/41002393 | PubMed |
Genes57
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36923538
GET https://conductscience.org/api/papers/v1/36923538/references?page=2